JP7407193B2 - 可変の複製多重ｐｃｒを使用した配列決定方法 - Google Patents

可変の複製多重ｐｃｒを使用した配列決定方法 Download PDF

Info

Publication number
JP7407193B2
JP7407193B2 JP2021531204A JP2021531204A JP7407193B2 JP 7407193 B2 JP7407193 B2 JP 7407193B2 JP 2021531204 A JP2021531204 A JP 2021531204A JP 2021531204 A JP2021531204 A JP 2021531204A JP 7407193 B2 JP7407193 B2 JP 7407193B2
Authority
JP
Japan
Prior art keywords
sequence
sample
reactions
variation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513173A (ja
JP2022513173A5 (enExample
Inventor
プラノル，ヴィンセント
フォーシュー，ティム
ウッドハウス，サミュエル
ローソン，アンドリュー
スミス，マシュー
Original Assignee
イニヴァータ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イニヴァータ リミテッド filed Critical イニヴァータ リミテッド
Publication of JP2022513173A publication Critical patent/JP2022513173A/ja
Publication of JP2022513173A5 publication Critical patent/JP2022513173A5/ja
Application granted granted Critical
Publication of JP7407193B2 publication Critical patent/JP7407193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Mathematical Optimization (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Bioethics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Operations Research (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021531204A 2018-08-08 2019-08-02 可変の複製多重ｐｃｒを使用した配列決定方法 Active JP7407193B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716082P 2018-08-08 2018-08-08
US62/716,082 2018-08-08
PCT/IB2019/056625 WO2020031048A1 (en) 2018-08-08 2019-08-02 Method of sequencing using variable replicate multiplex pcr

Publications (3)

Publication Number Publication Date
JP2022513173A JP2022513173A (ja) 2022-02-07
JP2022513173A5 JP2022513173A5 (enExample) 2022-07-29
JP7407193B2 true JP7407193B2 (ja) 2023-12-28

Family

ID=67953830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531204A Active JP7407193B2 (ja) 2018-08-08 2019-08-02 可変の複製多重ｐｃｒを使用した配列決定方法

Country Status (9)

Country Link
US (4) US11566274B2 (enExample)
EP (1) EP3833783B1 (enExample)
JP (1) JP7407193B2 (enExample)
KR (1) KR102910949B1 (enExample)
CN (1) CN112601824A (enExample)
AU (1) AU2019319711B2 (enExample)
BR (1) BR112021002189A2 (enExample)
CA (1) CA3107376A1 (enExample)
WO (1) WO2020031048A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
JP7407193B2 (ja) 2018-08-08 2023-12-28 イニヴァータ リミテッド 可変の複製多重ｐｃｒを使用した配列決定方法
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
WO2023012521A1 (en) * 2021-08-05 2023-02-09 Inivata Limited Highly sensitive method for detecting cancer dna in a sample
JP2023536325A (ja) * 2020-08-05 2023-08-24 イニヴァータ リミテッド 試料中のがんｄｎａを検出するための高感度の方法
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
EP4652604A1 (en) 2023-01-18 2025-11-26 Inivata Ltd. Cancer-associated genetic variant filtering using mutational signatures
WO2026006629A1 (en) 2024-06-27 2026-01-02 Personalis, Inc. System and method for management of compressed sequencing files

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526073A (ja) 2012-07-24 2015-09-10 ナテラ， インコーポレイテッド 高度多重ｐｃｒ法および組成物
US20160369333A1 (en) 2010-05-18 2016-12-22 Natera, Inc. Methods for simultaneous amplification of target loci
US20170204455A1 (en) 2014-07-18 2017-07-20 Cancer Research Technology Limited Method for Detecting a Genetic Variant
WO2018083467A1 (en) 2016-11-02 2018-05-11 Ucl Business Plc Method of detecting tumour recurrence

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948902A (en) 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
US7727720B2 (en) 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US20040086892A1 (en) 2002-11-06 2004-05-06 Crothers Donald M. Universal tag assay
US20050233340A1 (en) 2004-04-20 2005-10-20 Barrett Michael T Methods and compositions for assessing CpG methylation
US20060263789A1 (en) 2005-05-19 2006-11-23 Robert Kincaid Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
US20070068573A1 (en) 2005-08-22 2007-03-29 Applera Corporation Device and method for microfluidic control of a first fluid in contact with a second fluid, wherein the first and second fluids are immiscible
WO2007133710A2 (en) 2006-05-11 2007-11-22 Raindance Technologies, Inc. Microfluidic devices and methods of use thereof
AU2008255569A1 (en) 2007-06-01 2008-12-04 Monoquant Pty Ltd A method for DNA breakpoint analysis
US20110230372A1 (en) * 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
US9524369B2 (en) 2009-06-15 2016-12-20 Complete Genomics, Inc. Processing and analysis of complex nucleic acid sequence data
WO2011140187A2 (en) 2010-05-04 2011-11-10 University Of Rochester Detecting chromosomal rearrangement
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
EP3225697A3 (en) * 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
HK1199745A1 (en) 2011-09-09 2015-07-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for obtaining a sequence
GB201301857D0 (en) 2013-02-01 2013-03-20 Selvi Ozan Method
CN105102635B (zh) 2013-03-15 2020-09-25 生命技术公司 肺癌的分类和可行性指数
US20160032396A1 (en) 2013-03-15 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Identification and Use of Circulating Nucleic Acid Tumor Markers
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
EP3071706B1 (en) 2013-11-21 2018-04-25 Assistance Publique-Hôpitaux de Paris Method for detecting chromosomal rearrangements
CN111534580B (zh) 2013-12-28 2024-06-04 夸登特健康公司 用于检测遗传变异的方法和系统
CN107002123A (zh) * 2014-08-14 2017-08-01 生命技术公司 多重转录组分析
US20170283854A1 (en) 2014-09-05 2017-10-05 University Of Florida Research Foundation, Inc. Multiplexed pcr assay for high throughput genotyping
US11149305B2 (en) * 2015-01-23 2021-10-19 Washington University Detection of rare sequence variants, methods and compositions therefor
US20160275240A1 (en) 2015-02-18 2016-09-22 Nugen Technologies, Inc. Methods and compositions for pooling amplification primers
WO2016201142A1 (en) 2015-06-09 2016-12-15 Life Technologies Corporation Methods, systems, compositions, kits, apparatus and computer-readable media for molecular tagging
AU2016363113A1 (en) 2015-12-03 2018-06-07 Alfred Health Monitoring treatment or progression of myeloma
CN106282356B (zh) * 2016-08-30 2019-11-26 天津诺禾医学检验所有限公司 一种基于扩增子二代测序点突变检测的方法及装置
GB201615486D0 (en) 2016-09-13 2016-10-26 Inivata Ltd Methods for labelling nucleic acids
CN106834275A (zh) * 2017-02-22 2017-06-13 天津诺禾医学检验所有限公司 ctDNA超低频突变检测文库的构建方法、试剂盒及文库检测数据的分析方法
GB201709675D0 (en) 2017-06-16 2017-08-02 Inivata Ltd Method for detecting genomic rearrangements
WO2019043059A1 (en) 2017-08-30 2019-03-07 Symphogen A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES
EP3682035B1 (en) * 2017-09-15 2025-02-05 The Regents of the University of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
GB201804641D0 (en) 2018-03-22 2018-05-09 Inivata Ltd Methods of sequencing nucleic acids and error correction of sequence reads
GB201804642D0 (en) 2018-03-22 2018-05-09 Inivata Ltd Methods of labelling nucleic acids
EP3784805A1 (en) 2018-04-23 2021-03-03 Inivata Limited Method for predicting and monitoring response to an immune checkpoint inhibitor
US20210040564A1 (en) 2018-04-23 2021-02-11 Inivata Ltd. Method for predicting and monitoring response to an immune checkpoint inhibitor
US10329627B1 (en) 2018-04-23 2019-06-25 Inivata Ltd. Method for predicting and monitoring response to an immune checkpoint inhibitor
JP7407193B2 (ja) 2018-08-08 2023-12-28 イニヴァータ リミテッド 可変の複製多重ｐｃｒを使用した配列決定方法
US11377698B2 (en) 2018-09-05 2022-07-05 Inivata Ltd. Method of treating a cancer patient without the need for a tissue biopsy
EP4219763A3 (en) 2018-12-12 2023-08-16 Inivata Ltd. Method for quantifying gene fusion dna
US10533214B2 (en) 2018-12-21 2020-01-14 Inivata Ltd. Method for measuring mutational load
WO2020174406A1 (en) 2019-02-28 2020-09-03 Inivata Ltd. Method for quantifying the amount of a target sequence in a nucleic acid sample
WO2021028768A1 (en) 2019-08-13 2021-02-18 Inivata Ltd. METHOD FOR ALTERING THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS BASED ON ANALYSIS OF ctDNA
JP2023536325A (ja) 2020-08-05 2023-08-24 イニヴァータ リミテッド 試料中のがんｄｎａを検出するための高感度の方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160369333A1 (en) 2010-05-18 2016-12-22 Natera, Inc. Methods for simultaneous amplification of target loci
JP2015526073A (ja) 2012-07-24 2015-09-10 ナテラ， インコーポレイテッド 高度多重ｐｃｒ法および組成物
US20170204455A1 (en) 2014-07-18 2017-07-20 Cancer Research Technology Limited Method for Detecting a Genetic Variant
WO2018083467A1 (en) 2016-11-02 2018-05-11 Ucl Business Plc Method of detecting tumour recurrence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int. J. Legal. Med.，2014年，Vol.128，pp.259-267

Also Published As

Publication number Publication date
KR102910949B1 (ko) 2026-01-09
US20230227890A1 (en) 2023-07-20
JP2022513173A (ja) 2022-02-07
EP3833783B1 (en) 2024-10-02
EP3833783A1 (en) 2021-06-16
US11566274B2 (en) 2023-01-31
WO2020031048A1 (en) 2020-02-13
US12378595B2 (en) 2025-08-05
US20200157604A1 (en) 2020-05-21
US20240110224A1 (en) 2024-04-04
CA3107376A1 (en) 2020-02-13
KR20210044249A (ko) 2021-04-22
AU2019319711A1 (en) 2021-02-11
US20250340926A1 (en) 2025-11-06
US11788116B2 (en) 2023-10-17
BR112021002189A2 (pt) 2021-05-04
AU2019319711B2 (en) 2025-08-28
CN112601824A (zh) 2021-04-02

Similar Documents

Publication Publication Date Title
US12378595B2 (en) Method for the analysis of minimal residual disease
US12258626B2 (en) Methods and systems for detecting genetic variants
JP7119014B2 (ja) まれな変異およびコピー数多型を検出するためのシステムおよび方法
US20240132965A1 (en) Highly sensitive method for detecting cancer dna in a sample
CN114574581A (zh) 检测稀有突变和拷贝数变异的系统和方法
US20230304084A1 (en) Method for quantifying the amount of a target sequence in a sample
US20250270629A1 (en) Method for amplifying a genomic sample
US12247249B2 (en) Method for amplifying a genomic sample
WO2023012521A1 (en) Highly sensitive method for detecting cancer dna in a sample
JP2026063177A (ja) 試料中のがんｄｎａを検出するための高感度の方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231218

R150 Certificate of patent or registration of utility model

Ref document number: 7407193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150